According to a literature survey, Each year in the United States, 1.1 million burn injuries require medical attention. Approximately 50,000 of these require hospitalization; 20,000 have major burns involving at least 25 percent of their total body surface, and approximately 4,500 of these people die. Up to 10,000 people in the United States die every year of burn-related infections. According to Thelansis Research, around 100% of cases reported mild to moderate, moderate to severe, and severe cases of required pain medication, however the Opioid for moderate to severe pain Plus non-opioid With/without adjuvant analgesic are being used to address as a solution.
Comprehensive insight on patient segmentation based on age, sex, grade of burn (First grade, Second grade superficial, Deep second grade, and Third grade), Pain types (Acute, Breakthrough pain, Resting Pain, Chronic Pain, and Neuropathic pain), Severity (Mild, Moderate, Moderate to Severe, and Severe), Signs & Symptoms, Clinical Manifestations, Treatment types (Opiates, Anticonvulsant medications, Antidepressants, and others) has been provided into the epidemiology section of the Burn Pain and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Helixmith Co., Ltd., Johnson & Johnson, Mallinckrodt, Cumberland Pharmaceuticals, and Amneal Pharma-ceuticals, LLC. Apart from the above companies like WEX Pharmaceutical is planning carried clinical study for its novel Halneuron, the asset is currently under the early stage of development.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,